Elekta Revenue Hits SEK 4.76B, Projects Growth to 2027
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
elektaradiation-therapy
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Elekta AB announced financial results on 28 May 2026 for its fiscal fourth quarter, reporting non-GAAP earnings of SEK 0.57 per share and quarterly revenue of SEK 4.76 billion. The Swedish medical technology company also provided its initial formal financial outlook for the upcoming 2026/27 fiscal year, marking a significant step in its post-transformation communication strategy. This forward guidance sets expectations for a key period following years of operational restructuring and product portfolio realignment.
The current macro backdrop for capital-intensive healthcare equipment is defined by moderately elevated interest rates, with the Riksbank's policy rate at 3.75% and the US 10-year Treasury yield near 4.3%. Funding for large hospital capital expenditures remains under scrutiny, making consistent execution and clear visibility vital for medical technology manufacturers. Elekta's decision to issue formal annual guidance for the first time signals management confidence that a multi-year operational overhaul has reached a point of stability.
Elekta's last major strategic pivot concluded in 2024, focusing its portfolio exclusively on radiation therapy and radiosurgery after divesting non-core assets. The company's prior earnings calls emphasized operational improvements and order book strength but refrained from providing concrete annual financial targets. The 2026/27 outlook represents a milestone in transitioning from a restructuring narrative to a growth story, directly addressing investor demands for greater financial predictability in a competitive sector.
The catalyst for this enhanced transparency is likely a combination of a stabilized order backlog and improved supply chain predictability. Major component shortages that plagued the global medical device industry through 2025 have largely normalized. This normalization allows for more accurate production scheduling and revenue recognition, enabling management to commit to a full-year financial framework with reduced operational risk.
The SEK 4.76 billion revenue figure represents the company's top-line performance for the quarter ending in April 2026. The non-GAAP EPS of SEK 0.57 provides a view of profitability excluding certain one-time restructuring and integration costs. A year-over-year comparison shows growth from the year-ago quarter's revenue of SEK 4.52 billion and non-GAAP EPS of SEK 0.49, indicating a revenue increase of approximately 5.3% and an earnings per share increase of 16.3%.
| Metric | Q4 2026 Result | Year-Ago Quarter (Q4 2025) | Change |
|---|---|---|---|
| Revenue (SEK B) | 4.76 | 4.52 | +0.24 B (+5.3%) |
| Non-GAAP EPS (SEK) | 0.57 | 0.49 | +0.08 (+16.3%) |
Peer performance provides context. Sector competitor Varian Medical Systems, a division of Siemens Healthineers, reported quarterly organic growth of 7% in its latest results. The broader iShares Global Medical Devices ETF (IXJ) has returned 4.2% year-to-date, underperforming the S&P 500's 8.1% gain over the same period. Elekta's market capitalization stands at approximately SEK 85 billion, positioning it as a mid-cap specialist within the global healthcare equipment universe.
The provision of formal fiscal year guidance is a significant positive for Elekta's investment profile, reducing the uncertainty premium typically assigned to turnaround stories. This development directly benefits long-term institutional holders seeking stable cash flow visibility, such as Swedish pension funds AP1 and AP4, which are known shareholders. The immediate market reaction will test whether reduced uncertainty translates into a higher valuation multiple, moving the stock closer to its peer group average.
Second-order effects include potential positive sentiment spillover into the niche radiation oncology supply chain. Key suppliers like IBA (IONB.BR), which provides proton therapy systems and components, and Civco Radiotherapy, a positioning and immobilization solutions provider, may see increased order visibility. Conversely, heightened competitive intensity could pressure smaller, pure-play radiosurgery firms like Zap Surgical Systems, which lack Elekta's scale and service network.
A key limitation of the outlook is its dependence on the timing of large, lumpy orders from public hospital networks, which are subject to budgetary approvals and political cycles. A slowdown in Chinese healthcare infrastructure spending or further delays in the US VA hospital modernization program could materially impact the guidance's achievability. The counter-argument is that Elekta's service and software revenue stream, which is more recurring, now constitutes over 30% of total sales, providing a buffer against equipment sales volatility.
Positioning data from recent exchange filings shows a net increase in long positions by dedicated healthcare funds throughout Q1 2026. Flow analysis indicates money is rotating into high-specialization medical technology names as a defensive growth play within the broader healthcare sector, which is facing pricing pressure in pharmaceuticals and patient volume uncertainty in providers.
Investors should monitor Elekta's order intake announcements, particularly for its next-generation Elekta Harmony linear accelerator platform, for confirmation of commercial momentum. The next scheduled catalyst is the company's Capital Markets Day, typically held in September, where management will likely provide deeper financial modeling assumptions and long-term margin targets. The Q1 2026/27 earnings report, expected in late August 2026, will offer the first checkpoint against the new annual guidance framework.
Key levels to watch include the SEK 90 billion market capitalization threshold, a level the stock has not sustained since 2022. On a technical basis, the share price faces resistance near SEK 185, its 200-week moving average. The yield on Elekta's outstanding senior unsecured bonds, currently around 4.8%, will be a barometer of credit market perception of the firm's strengthened financial guidance.
Broader sector sentiment will be influenced by the Q2 2026 earnings season for US hospital chains like HCA Healthcare, as their capital expenditure commentary provides a leading indicator for medical device demand. Regulatory updates from the US FDA regarding software as a medical device (SaMD) classifications could also impact the valuation of Elekta's oncology information systems suite, a key growth driver.
Elekta's reported 5.3% year-over-year revenue growth in its recent quarter trails the 7% organic growth reported by Varian Medical Systems for a comparable period. The key differentiator is geographic mix; Varian holds a stronger market share in North America, where hospital capital spending has been more resilient. Elekta has traditionally derived a larger portion of its sales from Europe and emerging markets, which have seen more budgetary pressure. The margin profile is another contrast, with Varian generally maintaining higher operating margins due to greater service contract penetration and manufacturing scale within the Siemens ecosystem.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.